Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Rajiv Singh

Neurology South Miami, FL Medical Doctor

NPI 1023451770 CMS profile 2784229

7540 Sw 59Th Ct Apt 14, South Miami, FL 33143

Open in the dashboard

General payments

$1,891

44 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Rajiv Singh of South Miami, FL is reported in the CMS Open Payments database as having received $1,891 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 1
2020 General $335 7
2019 General $1,431 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajiv Singh
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rajiv Singh were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rajiv Singh Neurology median Middle half National median
2019 $1,431 $474 $118–$2,177 $163
2020 $335 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $125 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. UCB, Inc. $476 10 payments
  2. Amgen Inc. $312 9 payments
  3. Biogen, Inc. $235 2 payments
  4. ACADIA Pharmaceuticals Inc $192 7 payments
  5. Teva Pharmaceuticals USA, Inc. $188 5 payments
  6. US WorldMeds, LLC $149 1 payment
  7. EMD Serono, Inc. $122 2 payments
  8. Genzyme Corporation $116 1 payment
  9. Lilly USA, LLC $63 5 payments
  10. NuVasive, Inc. $22 1 payment
  11. Other $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,715 39 payments
  2. Education $160 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17 1 payment
Products named General payments · program years 2019–2023
  1. AIMOVIG $312 9 payments
  2. Briviact $271 5 payments
  3. NUPLAZID $192 7 payments
  4. Ajovy $188 5 payments
  5. MYOBLOC $149 1 payment
  6. LEMTRADA $116 1 payment
  7. TECFIDERA $112 1 payment
  8. Mavenclad $105 1 payment
  9. EMGALITY $63 5 payments
  10. Vimpat $45 1 payment
  11. Other $67 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Psychiatry & Neurology: 100

Drug cost

$279

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amitriptyline Hcl Generic 19 $279

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record